Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Aurexis in Staphylococcus Aureus Bacteremia
NCT00198302Phase 2Completed
- Sponsor
- Bristol Myers Squibb
- Modality
- Monoclonal Antibodies
01
Overview
A Phase 2 trial of tefibazumab in Staphylococcus aureus bacteremia (SAB), sponsored by Bristol Myers Squibb. Status: completed.
02
Drugs
tefibazumab
03
Conditions
Staphylococcus aureus bacteremia (SAB)
Beyond the preview
Go deeper on NCT00198302.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00198302.